Stem cell therapy for Peripheral Neuropathy — for patients from United Kingdom

If you are researching Peripheral Neuropathy treatment from the United Kingdom, the obstacle is usually access or cost: standard options have plateaued, and regenerative therapy at home runs to €4,640–€46,400. Stem Plus offers the same European GMP standard for a fraction of that — and an easy, mostly visa-free trip.

How Peripheral Neuropathy is treated

Peripheral neuropathy encompasses diverse conditions—diabetic, idiopathic, chemotherapy-induced, ischaemic—characterised by progressive nerve fibre loss, demyelination, and sensorimotor dysfunction. Stem cell therapies exploit multiple pathways: placental mesenchymal stem cells (MSCs) secrete neurotrophic factors (NGF, GDNF, VEGF) that promote nerve regeneration and angiogenesis; neurogenic cells differentiate into functional neurons to replace damaged fibres; exosomes deliver growth factor cargo directly into affected peripheral tissues. The rationale combines neuroprotection (halting further degeneration), neuroregenerative repair (sprouting of surviving axons), and vascular restoration (improving ischaemic neuropathy). Forty-six registered trials investigate efficacy across neuropathy subtypes; eight actively recruit, indicating expanding clinical capacity and commercial interest. It is delivered under a physician-led protocol and designed to complement your existing care.

Your cost from United Kingdom

Cost ranges are indicative market figures for planning, not quotes.